MKP11093
Mankind gets CDSCO nod for Phase 1 clinical trials for molecule to treat autoimmune disordersMankind Pharma has received CDSCO approval to begin Phase 1 clinical trials for MKP11093, a molecule targeting multiple autoimmune disorder...
- Load More